Therapeutic developments in cytomegalovirus retinitis.

Area of Science:

• Ophthalmology
• Infectious Diseases
• Virology

Background:

• Highly active antiretroviral therapy (HAART) has decreased the incidence of cytomegalovirus (CMV) retinitis in AIDS patients.
• Despite HAART, HIV patients, particularly those with treatment failure, remain at risk for CMV retinitis, potentially leading to vision loss.

Purpose of the Study:

• To review current and emerging treatments for cytomegalovirus (CMV) retinitis in the context of HIV/AIDS.
• To discuss the efficacy, administration, and side effect profiles of various anti-CMV agents.

Main Methods:

• Review of existing literature on CMV retinitis treatments.
• Comparison of systemic and local therapies, including ganciclovir, foscarnet, cidofovir, and intravitreal agents.
• Discussion of novel agents and their developmental status.

Main Results:

• Ganciclovir, foscarnet, and cidofovir are established treatments with varying efficacy and toxicity profiles.
• Local therapies, such as the intraocular ganciclovir implant and fomivirsen, offer high efficacy and good tolerability.
• Valganciclovir shows promise as an orally bioavailable prodrug of ganciclovir, simplifying treatment administration.

Conclusions:

• While HAART has reduced CMV retinitis, it remains a concern for some HIV patients.
• A range of treatment options exist, from traditional antivirals to local therapies and promising new agents like valganciclovir.
• Continued research into anti-CMV agents is important, though development has slowed due to the disease's decreased incidence.